At Tempus, we are changing the way precision oncology care is delivered. By leveraging the power of clinical and molecular data, we offer comprehensive genomic profiling services that are reshaping the way cancer is diagnosed and treated.
Our single platform is a one-stop-shop for all your cancer testing needs, with a comprehensive portfolio and a vast multimodal database, we are making precision medicine a reality for patients everywhere.
Maximize biomarker detection and identify more clinically actionable variants linked to targeted therapy options.
In a metastatic pan-cancer analysis of 1,448 patients with actionable variants, 9% of patients had unique actionable alterations found in liquid biopsy that were not detected in solid tumor alone.1
Enable a more complete understanding of clinically actionable fusions and altered splicing.
29% more patients, within a cohort of patients that had fusions discovered, were identified with a unique, clinically actionable fusion that matched to a targeted therapy with addition of RNA sequencing, compared to DNA sequencing alone.2
Provides accurate insight through true identification of somatic alterations and maximizes targeted therapy opportunities.
28% reduction in somatic false-positive calls, improving variant accuracy compared to a tumor-only analysis.3
Expansive and developing portfolio of algorithmic testing capabilities and digital pathology platform leveraging 6M+ de-identified research records.
Tempus One: the first step toward artificial intelligence enabled genomic reporting, to help you make data-driven precision medicine decisions.
Providing a comprehensive view of your patient’s molecular profile.
Identify patients with hereditary risk through streamlined cancer testing.
648 gene DNA sequencing panel
MSI Status, TMB
—IHC analysis of PD-L1 and MMR proteins
Whole-transcriptome RNA sequencing panel
—IHC analysis of PD-L1 and MMR proteins
648 gene DNA sequencing panel
105/523 gene ctDNA sequencing panel
MSI-H status, bTMB
36/77 gene panels for hereditary cancers
19,000+ gene DNA sequencing panel
TMB
—IHC analysis of PD-L1 and MMR proteins
TO, HRD, DPYD, UGT1A1, PurIST℠
We are a leading profiling partner in the incorporation of MSK OncoKB and NCCN Guidelines®4 into clinical reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.
Actionable molecular findings.
We are a leading profiling partner in the incorporation of MSK OncoKB and NCCN Guidelines®4 into clinical reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.
Increased therapeutic options by leveraging MSK OncoKB and NCCN Clinical Guidelines®4.
We are a leading profiling partner in the incorporation of MSK OncoKB and NCCN Guidelines®4 into clinical reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.
By combining clinical and molecular data, we provide you with insights into therapy resistance.
We are a leading profiling partner in the incorporation of MSK OncoKB and NCCN Guidelines®4 into clinical reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.
96% of patients matched to a clinical trial when Tempus NGS was combined with clinical data.3
We are a leading profiling partner in the incorporation of MSK OncoKB and NCCN Guidelines®4 into clinical reports, empowering physicians with clinically relevant findings that combine clinical and molecular data to guide personalized patient care.
Patient’s clinical history captured within the report.
View interactive and in-depth next-generation sequencing results in the context of a patient’s clinical history, filterable treatment applications and clinical trials, derived from our vast library of molecular profiling data.
To access the Hub platform, visit hub.securetempus.com, and select the “Request Access” button.
Available on both desktop and mobile devices.
Learn more
Take advantage of Tempus’ rapidly growing multimodal dataset capabilities to structure, unify, and normalize your data for clinical trial matching, precision medicine analytics, publications, and AI development.
Learn more
We want to make blood draw services as convenient as possible for your patients. For patients unable to visit a clinic, we can help to schedule a blood draw appointment at a location convenient to them.
To schedule an appointment, please call 800.739.4137 or utilize the Mobile Phlebotomy Request Form.
Approval of the financial assistance application is based on your household income and takes into account all life circumstances. Once a financial assistance application is submitted either online or over the phone, you will receive a decision at the time of submission.
Step 1
Apply for financial assistance online at access.tempus.com.
Step 2
If approved, you will know immediately about the maximum out-of-pocket cost of your testing.
Step 3
Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.
All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.
Tempus is working to make precision medicine a reality for cancer patients. Each person’s cancer and medical circumstances are unique. Tempus has a database of de-identified health information from many cancer patients. We believe we can improve cancer care and research, in the United States and abroad, by adding more de-identified health information to our database.
Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the Notice and Authorization for Medical Records form for more information.
This is the future of healthcare.